BRAF V600E/CRAF-IN-1,2499499-5

甲状腺癌的BRAF基因检测

率的45.7%(845/1,849)。有56 例PTC死亡病例，占总死亡率的3.0%。在这些死亡病例中，45例（80.4%）BRAF V600E突变阳性。该项研究证实BRAF V600E突变阳性与PTC患者死亡率增加相关。 ADx-ARMS®技术（特异引物双扩增系统）是厦门艾德自主研发的新型核酸检测技术，也是《中华病理学杂志》公布的“基因突变检测专家共识”中推荐的技术之一。AmoyDx® BRAF V600E基因突变检测试剂盒采用ADx-ARMS®专利技术，利用新型探针在实时PCR平台

Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma

V600 BRAF mutation was identified as an ideal target for clinical therapy due to its indispensable roles in supporting melanoma initiation and progression. Despite the fact that BRAF inhibitors (BRAFi) can elicit anti-tumor responses

Assaying for BRAF V600E in Tissue and Blood in Melanoma

The BrafV600E mutation has been detected in patients with metastatic melanoma, colon, thyroid, and other cancers. Studies suggested that tumors with this mutation are especially sensitive to BRAF inhibitors-hence the need to reliably